{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:35:18Z","timestamp":1787866518535,"version":"build-2784847793"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Ferring Pharmaceuticals, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40121-026-01374-9","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:34:10Z","timestamp":1781278450000},"page":"2071-2086","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct01925417","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02299570","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02589847","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03244644","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03931941","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05831189","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1185-4549","authenticated-orcid":false,"given":"Teena","family":"Chopra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Van Handel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Baggott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Orenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8880-4879","authenticated-orcid":false,"given":"Kelly","family":"Reveles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Guthmueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"1374_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.20","volume":"2","author":"WK Smits","year":"2016","unstructured":"Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1374_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12879-023-08096-0","volume":"23","author":"P Feuerstadt","year":"2023","unstructured":"Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023;23(1):132.","journal-title":"BMC Infect Dis"},{"issue":"12 Suppl 2","key":"1374_CR3","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1093\/infdis\/jiaa408","volume":"223","author":"CM Pike","year":"2021","unstructured":"Pike CM, Theriot CM. Mechanisms of colonization resistance against Clostridium difficile. J Infect Dis. 2021;223(12 Suppl 2):S194\u2013200.","journal-title":"J Infect Dis"},{"issue":"5","key":"1374_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/0897190013499521","volume":"26","author":"DD Depestel","year":"2013","unstructured":"Depestel DD, Aronoff DM. Epidemiology of Clostridium difficile infection. J Pharm Pract. 2013;26(5):464\u201375.","journal-title":"J Pharm Pract"},{"issue":"9","key":"1374_CR5","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1128\/JCM.00845-13","volume":"51","author":"VC Antharam","year":"2013","unstructured":"Antharam VC, Li EC, Ishmael A, Sharma A, Mai V, Rand KH, et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol. 2013;51(9):2884\u201392.","journal-title":"J Clin Microbiol"},{"issue":"8","key":"1374_CR6","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/MCG.0000000000001947","volume":"58","author":"P Feuerstadt","year":"2024","unstructured":"Feuerstadt P, Crawford CV, Tan X, Pokhilko V, Bancke L, Ng S, et al. Fecal microbiota, live-jslm for the prevention of recurrent Clostridioides difficile infection: subgroup analysis of PUNCH CD2 and PUNCH CD3. J Clin Gastroenterol. 2024;58(8):818\u201324.","journal-title":"J Clin Gastroenterol"},{"key":"1374_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211011953","volume":"14","author":"A Chaar","year":"2021","unstructured":"Chaar A, Feuerstadt P. Evolution of clinical guidelines for antimicrobial management of Clostridium difficile infection. Ther Adv Gastroenterol. 2021;14:17562848211011953.","journal-title":"Ther Adv Gastroenterol"},{"issue":"6","key":"1374_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","volume":"116","author":"CR Kelly","year":"2021","unstructured":"Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridium difficile infections. Am J Gastroenterol. 2021;116(6):1124\u201347.","journal-title":"Am J Gastroenterol"},{"key":"1374_CR9","first-page":"1","volume-title":"Clostridium difficile - A Comprehensive Overview","author":"L Fern\u00e1ndez-Garc\u00eda","year":"2017","unstructured":"Fern\u00e1ndez-Garc\u00eda L, Blasco L, L\u00f3pez-D\u00edaz M, Tom\u00e1s M. Clostridium difficile infection: pathogenesis, diagnosis and treatment. In: Enany S, editor. Clostridium difficile - A Comprehensive Overview. Rijeka: Croatia; 2017. p. 1\u201371."},{"issue":"7","key":"1374_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","volume":"66","author":"LC McDonald","year":"2018","unstructured":"McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1\u201348.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1374_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2223345","volume":"15","author":"AJ Gonzales-Luna","year":"2023","unstructured":"Gonzales-Luna AJ, Carlson TJ, Garey KW. Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies. Gut Microbes. 2023;15(1):2223345.","journal-title":"Gut Microbes"},{"issue":"9","key":"1374_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa1408913","volume":"372","author":"FC Lessa","year":"2015","unstructured":"Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825\u201334.","journal-title":"N Engl J Med"},{"key":"1374_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/1469-0691.12012","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely OA. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Clin Microbiol Infect. 2012;18:28\u201335.","journal-title":"Clin Microbiol Infect"},{"key":"1374_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/1469-0691.12046","volume":"18","author":"CP Kelly","year":"2012","unstructured":"Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18:21\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"1374_CR15","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","volume":"97","author":"LV McFarland","year":"2002","unstructured":"McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97(7):1769\u201375.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1374_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cmi.2014.08.017","volume":"21","author":"MA Olsen","year":"2015","unstructured":"Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2015;21(2):164\u201370.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"1374_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/13696998.2020.1724117","volume":"23","author":"P Feuerstadt","year":"2020","unstructured":"Feuerstadt P, Stong L, Dahdal DN, Sacks N, Lang K, Nelson WW. Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis. J Med Econ. 2020;23(6):603\u20139.","journal-title":"J Med Econ"},{"issue":"9","key":"1374_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.7326\/M16-0271","volume":"165","author":"CR Kelly","year":"2016","unstructured":"Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165(9):609\u201316.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1374_CR19","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","volume":"73","author":"S Johnson","year":"2021","unstructured":"Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029\u201344.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1374_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","volume":"166","author":"AF Peery","year":"2024","unstructured":"Peery AF, Kelly CR, Kao D, Vaughn BP, Lebwohl B, Singh S, et al. AGA clinical practice guideline on fecal microbiota based therapies for select gastrointestinal diseases. Gastroenterology. 2024;166(3):409\u201334.","journal-title":"Gastroenterology"},{"key":"1374_CR21","first-page":"1","volume":"9","author":"C Dowle","year":"2016","unstructured":"Dowle C. Faecal microbiota transplantation: a review of FMT as an alternative treatment for Clostridium difficile infection. Bio Horiz. 2016;9:1\u201314.","journal-title":"Bio Horiz"},{"key":"1374_CR22","unstructured":"REBYOTATM (fecal microbiota, live - jslm) suspension, for rectal use. Prescribing information. Rebiotix Inc.; 2022. Available from: https:\/\/www.ferringusa.com\/wp-content\/uploads\/sites\/12\/2022\/12\/9009000002_REBYOTA-PI_11-2022.pdf."},{"issue":"6","key":"1374_CR23","doi-asserted-by":"publisher","first-page":"e1022","DOI":"10.1093\/infdis\/jiae418","volume":"231","author":"KF Blount","year":"2025","unstructured":"Blount KF, Papazyan R, Ferdyan N, Srinivasan K, Gonzalez C, Shannon WD, et al. Microbiome and metabolome restoration after administration of fecal microbiota, live-jslm (REBYOTA\u00ae) for preventing recurrent Clostridioides difficile infection. J Infect Dis. 2025;231(6):e1022\u201333.","journal-title":"J Infect Dis"},{"issue":"1","key":"1374_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2520412","volume":"17","author":"J Claypool","year":"2025","unstructured":"Claypool J, Lindved G, Myers PN, Ward T, Nielsen HB, Blount KF. Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection. Gut Microbes. 2025;17(1):2520412.","journal-title":"Gut Microbes"},{"key":"1374_CR25","unstructured":"Ferring Pharmaceuticals announces availability of REBYOTA\u2122 (fecal microbiota, live \u2013 jslm) \u2013 the first and only FDA-approved microbiome-based treatment for the prevention of recurrence of C. diff infection in adults [press release]. Parsippany, NJ: Ferring Pharmaceuticals, February 14, 2023."},{"key":"1374_CR26","unstructured":"Ferring Inc. receives Health Canada approval for PrREBYOTA\u00ae (fecal microbiota, live) - a novel first-in-class microbiome-restoration therapy for the prevention of recurrence of C. diff infection. [press release]. Toronto, Ontario, Canada: Ferring Inc., March 6, 2025."},{"issue":"5","key":"1374_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/cid\/civ938","volume":"62","author":"R Orenstein","year":"2016","unstructured":"Orenstein R, Dubberke E, Hardi R, Ray A, Mullane K, Pardi DS, et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis. 2016;62(5):596\u2013602.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1374_CR28","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/cid\/ciy259","volume":"67","author":"ER Dubberke","year":"2018","unstructured":"Dubberke ER, Lee CH, Orenstein R, Khanna S, Hecht G, Gerding DN. Results from a randomized, placebo-controlled clinical trial of a RBX2660-a microbiota-based drug for the prevention of recurrent Clostridium difficile infection. Clin Infect Dis. 2018;67(8):1198\u2013204.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1374_CR29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40121-022-00744-3","volume":"12","author":"ER Dubberke","year":"2023","unstructured":"Dubberke ER, Orenstein R, Khanna S, Guthmueller B, Lee C. Final results from a phase 2b randomized, placebo-controlled clinical trial of RBX2660: a microbiota-based drug for the prevention of recurrent Clostridioides difficile infection. Infect Dis Ther. 2023;12(2):703\u20139.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1374_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07256-y","volume":"22","author":"R Orenstein","year":"2022","unstructured":"Orenstein R, Dubberke ER, Khanna S, Lee CH, Yoho D, Johnson S, et al. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infect Dis. 2022;22(1):245.","journal-title":"BMC Infect Dis"},{"issue":"15","key":"1374_CR31","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","volume":"82","author":"S Khanna","year":"2022","unstructured":"Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527\u201338.","journal-title":"Drugs"},{"issue":"1","key":"1374_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/cid\/ciae437","volume":"80","author":"P Feuerstadt","year":"2025","unstructured":"Feuerstadt P, Chopra T, Knapple W, Van Hise NW, Dubberke ER, Baggott B, et al. PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent Clostridioides difficile infection. Clin Infect Dis. 2025;80(1):43\u201351.","journal-title":"Clin Infect Dis"},{"key":"1374_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251339697","volume":"18","author":"S Khanna","year":"2025","unstructured":"Khanna S, Yoho D, Van Handel D, Clark BJ, Awad T, Guthmueller B, et al. Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA\u00ae) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial. Ther Adv Gastroenterol. 2025;18:17562848251339697.","journal-title":"Ther Adv Gastroenterol"},{"issue":"5","key":"1374_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad171","volume":"10","author":"P Feuerstadt","year":"2023","unstructured":"Feuerstadt P, Harvey A, Yoho DS, Garcia-Diaz JB, Knapple WL, Bancke L. Retrospective analysis of the safety and efficacy of fecal microbiota, live-jslm (REBYOTA\u2122) administered under enforcement discretion to patients with Clostridioides difficile infection. Open Forum Infect Dis. 2023;10(5):ofad171.","journal-title":"Open Forum Infect Dis"},{"key":"1374_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241239547","volume":"17","author":"WL Knapple","year":"2024","unstructured":"Knapple WL, Yoho DS, Sheh A, Thul J, Feuerstadt P. Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA\u00ae) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection. Ther Adv Gastroenterol. 2024;17:17562848241239547.","journal-title":"Ther Adv Gastroenterol"},{"key":"1374_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251396744","volume":"18","author":"S Khanna","year":"2025","unstructured":"Khanna S, Yoho D, Van Handel D, Clark BJ, Awad T, Guthmueller B, et al. Prevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA\u00ae) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial. Ther Adv Gastroenterol. 2025;18:17562848251396744.","journal-title":"Ther Adv Gastroenterol"},{"key":"1374_CR37","doi-asserted-by":"crossref","unstructured":"Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320\u201330.","DOI":"10.1056\/NEJMoa1910215"},{"issue":"4","key":"1374_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf117","volume":"12","author":"CD Alonso","year":"2025","unstructured":"Alonso CD, Tillotson GS, Bidell MR, Guthmueller B, Hoeyer F, Fischer M, et al. Safety and efficacy of fecal microbiota, live-jslm, in preventing recurrent Clostridioides difficile infection in participants who were mildly to moderately immunocompromised in the phase 3 PUNCH CD3-OLS study. Open Forum Infect Dis. 2025;12(4):ofaf117.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"1374_CR39","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1093\/ibd\/izae291","volume":"31","author":"JR Allegretti","year":"2025","unstructured":"Allegretti JR, Feuerstadt P, Knapple WL, Orenstein R, Pinton P, Sheh A, et al. Safety and efficacy of fecal microbiota, live-jslm (REBYOTA\u00ae), for the prevention of recurrent Clostridioides difficile infection in participants with inflammatory bowel disease in PUNCH CD3-OLS. Inflamm Bowel Dis. 2025;31(8):2112\u20132122.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"1374_CR40","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s40121-025-01208-0","volume":"14","author":"OC Aroniadis","year":"2025","unstructured":"Aroniadis OC, Guthmueller B, Dehlin K, Srivastava S, Feuerstadt P, Lembo A, et al. Safety and efficacy of fecal microbiota, live-jslm to prevent recurrent Clostridioides difficile infection in participants with irritable bowel syndrome. Infect Dis Ther. 2025;14(9):2157\u201369.","journal-title":"Infect Dis Ther"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01374-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01374-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01374-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:06:16Z","timestamp":1783616776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01374-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1374"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01374-9","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: Teena Chopra is a speaker and consultant for Ferring Pharmaceuticals, Inc. Daniel Van Handel is on a speaker\u2019s bureau for Ferring Pharmaceuticals, Inc. Brian Baggott declares that he has no conflicts of interest. Robert Orenstein participated on advisory boards for Rebiotix, Inc. Kelly Reveles serves as a scientific consultant for Ferring Pharmaceuticals, Inc. Sahil Khanna received research support from Vedanta and consulting fees from Takeda, Ferring, Rise, and ProbioTech. Beth Guthmueller was an employee of Ferring Pharmaceuticals, Inc. at the time this manuscript was developed. Shivam Srivastava is an employee of Ferring Pharmaceuticals A\/S.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Institutional review board approval was not required. All participants provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}